Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK Limited

Regeneron UK drug portfolio — 98 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Status
Public
HQ
Tarrytown, USA
Employees
16,715
Programs
493
Drugs
98
Patents
837
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Drug Pipeline

Regeneron UK pipeline

Portfolio lens on 98 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Regeneron UK drug portfolio — 98 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

98 compounds

  1. abacavir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved.

  2. abacavir sulfate

    US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.

    Target
    Human immunodeficiency virus type 1 reverse transcriptase
    Mechanism
    Human immunodeficiency virus type 1 reverse transcriptase inhibitor

  3. acetaminophen

    US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Cyclooxygenase inhibitor

  4. aflibercept

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Placenta growth factor.

    Target
    Placenta growth factor
    Mechanism
    Placenta growth factor inhibitor

  5. alcohol

    US regulatory status: approved.

  6. alirocumab

    Cardiovascular system (C10)

    US regulatory status: approved. Molecular target: Proprotein convertase subtilisin/kexin type 9.

    Target
    Proprotein convertase subtilisin/kexin type 9
    Mechanism
    Subtilisin/kexin type 9 inhibitor

  7. amlodipine besylate

    US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.

    Target
    Voltage-gated L-type calcium channel
    Mechanism
    Voltage-gated L-type calcium channel blocker

  8. anti-

    Development asset linked to Regeneron UK in public FDA and regional records.

  9. anti-melanoma mab fragments

    Various (V09)

    Various (V09) compound in Regeneron UK's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  10. anti-vegf

    Development asset linked to Regeneron UK in public FDA and regional records.

  11. antibody

    Development asset linked to Regeneron UK in public FDA and regional records.

  12. aspirin

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  13. atoltivimab

    US regulatory status: approved. Molecular target: Envelope glycoprotein.

    Target
    Envelope glycoprotein
    Mechanism
    Envelope glycoprotein inhibitor

  14. atorvastatin

    Development asset linked to Regeneron UK in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.

    Mechanism
    HMG-CoA reductase inhibitor

  15. binimetinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.

    Target
    Dual specificity mitogen-activated protein kinase kinase 1
    Mechanism
    Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

  16. calcium chloride

    US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.

    Mechanism
    Dihydrofolate reductase inhibitor

  17. capecitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  18. capsule

    Development asset linked to Regeneron UK in public FDA and regional records.

  19. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  20. casirivimab

    Antiinfectives for systemic use (J06)

    Antiinfectives for systemic use (J06) compound in Regeneron UK's portfolio. Molecular target: Spike glycoprotein.

    Target
    Spike glycoprotein
    Mechanism
    Spike glycoprotein inhibitor

  22. cemiplimab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Regeneron UK's portfolio. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  23. cemiplimab-rwlc

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  24. chop

    Development asset linked to Regeneron UK in public FDA and regional records.

  25. cisplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  26. colchicine

    Musculo-skeletal system (M04)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  27. combination

    Development asset linked to Regeneron UK in public FDA and regional records.

  28. control

    Development asset linked to Regeneron UK in public FDA and regional records.

  29. covid-19 vaccine (inactivated, adjuvanted, adsorbed)

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in Regeneron UK's portfolio. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response

  30. degarelix

    Antineoplastic and immunomodulating agents (L02)

    Antineoplastic and immunomodulating agents (L02) compound in Regeneron UK's portfolio. Mechanism: Gonadotropin-releasing hormone receptor antagonist.

    Mechanism
    Gonadotropin-releasing hormone receptor antagonist

  31. degarelix acetate

    US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.

    Target
    Gonadotropin-releasing hormone receptor
    Mechanism
    Gonadotropin-releasing hormone receptor antagonist

  32. dose

    Development asset linked to Regeneron UK in public FDA and regional records.

  33. dupilumab

    Dermatologicals (D11)

    US regulatory status: approved. Molecular target: Interleukin-4 receptor subunit alpha.

    Target
    Interleukin-4 receptor subunit alpha
    Mechanism
    Interleukin-4 receptor subunit alpha antagonist

  34. ebola zaire vaccine (rvsv∆g-zebov-gp, live)

    Development asset linked to Regeneron UK in public FDA and regional records. Molecular target: Envelope glycoprotein.

    Target
    Envelope glycoprotein
    Mechanism
    Envelope glycoprotein vaccine antigen

  35. encorafenib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Serine/threonine-protein kinase B-raf.

    Target
    Serine/threonine-protein kinase B-raf
    Mechanism
    Serine/threonine-protein kinase B-raf inhibitor

  36. epithelial

    Development asset linked to Regeneron UK in public FDA and regional records.

  37. estropipate

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  38. ethinyl estradiol

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  39. evinacumab

    Cardiovascular system (C10)

    Cardiovascular system (C10) compound in Regeneron UK's portfolio. Molecular target: Angiopoietin-related protein 3.

    Target
    Angiopoietin-related protein 3
    Mechanism
    Angiopoietin-related protein 3 inhibitor

  40. evinacumab-dgnb

    US regulatory status: approved. Molecular target: Angiopoietin-related protein 3.

    Target
    Angiopoietin-related protein 3
    Mechanism
    Angiopoietin-related protein 3 inhibitor

  41. fingolimod

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Mechanism: Sphingosine 1-phosphate receptor binding agent.

    Mechanism
    Sphingosine 1-phosphate receptor binding agent

  42. fluoxymesterone

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor agonist

  43. gemcitabine

    US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.

    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  44. hexachlorophene

    US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.

    Target
    Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
    Mechanism
    Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor

  45. hexocyclium methylsulfate

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.

    Target
    Muscarinic acetylcholine receptor M1
    Mechanism
    Muscarinic acetylcholine receptor M1 antagonist

  46. high-dose

    Development asset linked to Regeneron UK in public FDA and regional records.

  47. hydrocortisone

    Systemic hormonal preparations (H02)

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  48. hydromorphone

    Development asset linked to Regeneron UK in public FDA and regional records. Mechanism: Mu opioid receptor agonist.

    Mechanism
    Mu opioid receptor agonist

  49. injectable

    Development asset linked to Regeneron UK in public FDA and regional records.

  50. injection

    Development asset linked to Regeneron UK in public FDA and regional records.

  51. intravenous

    Development asset linked to Regeneron UK in public FDA and regional records.

  52. intravitreal

    Development asset linked to Regeneron UK in public FDA and regional records.

  53. ipilimumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.

    Target
    Cytotoxic T-lymphocyte protein 4
    Mechanism
    Cytotoxic T-lymphocyte protein 4 inhibitor

  54. ketorolac tromethamine

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  55. lamivudine

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  57. linvoseltamab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Regeneron UK's portfolio.

  59. malignant

    Development asset linked to Regeneron UK in public FDA and regional records.

  60. medroxyprogesterone acetate

    US regulatory status: approved. Molecular target: Progesterone receptor.

    Target
    Progesterone receptor
    Mechanism
    Progesterone receptor agonist

  61. monoclonal

    Development asset linked to Regeneron UK in public FDA and regional records.

  62. monotherapy

    Development asset linked to Regeneron UK in public FDA and regional records.

  64. odronextamab

    Nervous system (NOT)

    Nervous system (NOT) compound in Regeneron UK's portfolio. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  65. ophthalmic

    Development asset linked to Regeneron UK in public FDA and regional records.

  66. oxaliplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  67. pemetrexed disodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  68. pemetrexed sodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  69. penicillamine

    US regulatory status: approved. Molecular target: Copper.

    Target
    Copper
    Mechanism
    Copper chelating agent

  70. phenytoin sodium

    US regulatory status: approved. Molecular target: Sodium channel alpha subunit.

    Target
    Sodium channel alpha subunit
    Mechanism
    Sodium channel alpha subunit blocker

  71. placebo

    Development asset linked to Regeneron UK in public FDA and regional records.

  72. powder

    Development asset linked to Regeneron UK in public FDA and regional records.

  73. pozelimab-bbfg

    US regulatory status: approved. Molecular target: Complement C5.

    Target
    Complement C5
    Mechanism
    Complement C5 inhibitor

  74. prochlorperazine

    US regulatory status: approved. Molecular target: D(2) dopamine receptor.

    Target
    D(2) dopamine receptor
    Mechanism
    Dopamine D2 receptor antagonist

  75. protocol

    Development asset linked to Regeneron UK in public FDA and regional records.

  76. radiation

    Development asset linked to Regeneron UK in public FDA and regional records.

  77. ranibizumab

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  78. ravulizumab

    Antineoplastic and immunomodulating agents (L04)

    Antineoplastic and immunomodulating agents (L04) compound in Regeneron UK's portfolio. Molecular target: Complement C5.

    Target
    Complement C5
    Mechanism
    Complement C5 inhibitor

  79. ravulizumab-cwvz

    US regulatory status: approved. Molecular target: Complement C5.

    Target
    Complement C5
    Mechanism
    Complement C5 inhibitor

  80. rilonacept

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-1 beta.

    Target
    Interleukin-1 beta
    Mechanism
    Interleukin-1 beta inhibitor

  81. rosuvastatin

    Development asset linked to Regeneron UK in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.

    Mechanism
    HMG-CoA reductase inhibitor

  82. saline

    Development asset linked to Regeneron UK in public FDA and regional records.

  83. sarilumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.

    Target
    Interleukin-6 receptor subunit alpha
    Mechanism
    Interleukin-6 receptor alpha subunit antagonist

  84. sars-cov-

    Development asset linked to Regeneron UK in public FDA and regional records.

  85. simvastatin

    US regulatory status: approved. Molecular target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

    Target
    3-hydroxy-3-methylglutaryl-coenzyme A reductase
    Mechanism
    HMG-CoA reductase inhibitor

  86. solution

    Development asset linked to Regeneron UK in public FDA and regional records.

  87. statin

    Development asset linked to Regeneron UK in public FDA and regional records.

  88. stro-

    Development asset linked to Regeneron UK in public FDA and regional records.

  89. subcutaneous

    Development asset linked to Regeneron UK in public FDA and regional records.

  90. t-cell

    Development asset linked to Regeneron UK in public FDA and regional records.

  91. therapy

    Development asset linked to Regeneron UK in public FDA and regional records.

  92. ticarcillin disodium

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  93. tirzepatide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Gastric inhibitory polypeptide receptor.

    Target
    Gastric inhibitory polypeptide receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  94. topotecan

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Regeneron UK's portfolio. Mechanism: DNA topoisomerase I, mitochondrial inhibitor.

    Mechanism
    DNA topoisomerase I, mitochondrial inhibitor

  95. tretinoin

    US regulatory status: approved. Molecular target: Retinoic acid receptor.

    Target
    Retinoic acid receptor
    Mechanism
    Retinoic acid receptor agonist

  98. ziv-aflibercept

    US regulatory status: approved. Molecular target: Placenta growth factor.

    Target
    Placenta growth factor
    Mechanism
    Placenta growth factor inhibitor

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.